# US 2004/0001828 A1 · Treatment methods using anti-CD22 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0001828 A1
- Document ID: US20040001828A1
- Status: Published application
- Kind: A1
- Application number: 10/371,797
- Filed: 2003-02-21
- Published: 2004-01-01
- Earliest claimed: 2002-02-21
- Inventors: Joseph Tuscano; Thomas F. Tedder
- Web page: https://patentgrep.com/patent/US20040001828A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 39/39533: {against materials from animals}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/16: for decreasing, blocking or antagonising the activity of the thyroid hormones
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).

## Claims

### Claim 1

A method for treating a human patient diagnosed with a B-cell malignancy, comprising (1) administering to said human patient an effective amount of a blocking anti-CD22 monoclonal antibody binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22) of SEQ ID NO: 1, and (2) monitoring the response of said malignancy to said treatment.

### Claim 2 (depends on 1)

The method of claim 1 wherein said antibody binds to essentially the same epitope of an antibody selected from the group consisting of HB22-7 (HB 11347), HB22-23 (HB11349), HB22-33, HB22-5, HB22-13, and HB22-196.

### Claim 3 (depends on 2)

The method of claim 2 wherein said antibody binds to essentially the same epitope as an antibody selected from the group consisting of HB22-7 (HB 11347), HB22-23 (HB 11349), and HB22-33.

### Claim 4 (depends on 3)

The method of claim 3 wherein said antibody binds to essentially the same epitope as HB22-7.

### Claim 5 (depends on 3)

The method of claim 3 wherein said antibody binds to essentially the same epitope as HB22-33.

### Claim 6 (depends on 1)

The method of claim 1 wherein said antibody blocks CD22 binding to its ligand by at least about 70%.

### Claim 7 (depends on 1)

The method of claim 1 wherein said antibody blocks CD22 binding to its ligand by at least about 80%.

### Claim 8 (depends on 1)

The method of claim 1 wherein said B-cell malignancy is localized.

### Claim 9 (depends on 1)

The method of claim 1 wherein said B-cell malignancy is selected from the group consisting of B-cell subtype of non-Hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia, hairy cell leukemia, and prolymphocytic leukemia.

### Claim 10 (depends on 1)

The method of claim 1 wherein said treatment is unaccompanied by any other treatment of malignant B cells.

### Claim 11 (depends on 1)

The method of claim 1 wherein said treatment is unaccompanied by radiation therapy.

### Claim 12 (depends on 1)

The method of claim 1 wherein said treatment is unaccompanied by chemotherapy.

### Claim 13 (depends on 1)

The method of claim 1 wherein said treatment is unaccompanied by radioimmunotherapy (RIT) or combined modality radioimmunotherapy (CMRIT).

### Claim 14 (depends on 10)

The method of claim 10 wherein treatment with said antibody alone provides improved cure rate in a Raji lymphoma xenograft model when compared to combination treatment with said antibody and radioimmunotherapy.

### Claim 15 (depends on 10)

The method of claim 10 wherein treatment with said antibody alone provides increased survival in a Raji lymphoma xenograft model when compared to combination treatment with said antibody and radioimmunotherapy.

### Claim 16 (depends on 10)

The method of claim 10 wherein treatment with said antibody alone provides superior tumor volume reduction in a Raji lymphoma xenograft model when compared to combination treatment with said antibody and radioimmunotherapy.

### Claim 17 (depends on 1)

The method of claim 1 wherein said antibody is a fragment of a complete antibody.

### Claim 18 (depends on 17)

The method of claim 17 wherein said antibody is selected from the group consisting of Fab, Fab′, F(ab′)2, and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments.

### Claim 19 (depends on 1)

The method of claim 1 wherein said antibody has an additional antigen-specificity.

### Claim 20 (depends on 19)

The method of claim 19 wherein said antibody is a bispecific antibody.

### Claim 21 (depends on 20)

The method of claim 20 wherein said antibody additionally binds to another epitope of CD22.

### Claim 22 (depends on 1)

The method of claim 1 wherein said antibody is chimeric.

### Claim 23 (depends on 1)

The method of claim 1 wherein said antibody is humanized.

### Claim 24 (depends on 1)

The method of claim 1 wherein said antibody is human.

### Claim 25 (depends on 1)

The method of claim 1 wherein said antibody is administered intravenously.

### Claim 26 (depends on 25)

The method of claim 25 wherein said antibody is administered by weekly intravenous infusions.

### Claim 27 (depends on 6)

The method of claim 6 wherein the response to said treatment is monitored by following shrinkage of a solid B-cell tumor.

### Claim 28 (depends on 27)

The method of claim 27 wherein shrinkage is monitored by magnetic resonance imaging (MRI).

### Claim 29 (depends on 1)

The method of claim 1 wherein said antibody comprises a heavy chain comprising a VH sequence having at least about 95% sequence identity with the sequence of amino acids 1 to 100 of SEQ ID NO: 9 (HB22-5 VH sequence); or amino acids 1 to 97 of SEQ ID NO: 11 (HB22-7 VH sequence); or amino acids 1 to 100 of SEQ ID NO: 13 (HB22-3 VH sequence); or amino acids 1 to 100 of SEQ ID NO: 15 (HB22-23 VH sequence); or amino acids 1 to 98 of SEQ ID NO: 17 (HB22-33 VH sequence); or amino acids 1 to 100 of SEQ ID NO: 19 (HB22-196 VH sequence).

### Claim 30 (depends on 29)

The method of claim 29 wherein said antibody comprises a heavy chain comprising a VH sequence having at least about 95% sequence identity with the sequence of amino acids 1 to 97 of SEQ ID NO: 11 (HB22-7 VH sequence); or amino acids 1 to 100 of SEQ ID NO: 15 (HB22-23 VH sequence); or amino acids 1 to 98 of SEQ ID NO: 17 (HB22-33 VH sequence).

### Claim 31 (depends on 30)

The method of claim 30 wherein said antibody comprises a VH sequence selected from the group consisting of amino acids 1 to 97 of SEQ ID NO: 11 (HB22-7 VH sequence); amino acids 1 to 100 of SEQ ID NO: 15 (HB22-23 VH sequence); and amino acids 1 to 98 of SEQ ID NO: 17 (HB22-33 VH sequence).

### Claim 32 (depends on 1)

The method of claim 1 wherein said antibody comprises a light chain comprising a Vκ sequence having at least about 95% sequence identity with the amino acid sequence of SEQ ID NO: 21 (HB22-5 Vκ sequence); or SEQ ID NO: 23 (HB22-7 Vκ sequence); or SEQ ID NO: 25 (HB22-13 Vκ sequence); or SEQ ID NO: 27 (HB22-23 Vκ sequence); or SEQ ID NO: 29 (HB22-33 Vκ sequence); or SEQ ID NO: 31 (HB22-196 Vκ sequence).

### Claim 33 (depends on 32)

The method of claim 32 wherein said antibody comprises a light chain comprising a Vκ sequence having at least about 95% sequence identity with the amino acid sequence of SEQ ID NO: 23 (HB22-7 Vκ sequence); or SEQ ID NO: 27 (HB22-23 Vκ sequence); or SEQ ID NO: 29 (HB22-33 Vκ sequence).

### Claim 34 (depends on 33)

The method of claim 33 wherein said antibody comprises a Vκ sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 23 (HB22-7 Vκ sequence); SEQ ID NO: 27 (HB22-23 Vκ sequence); and SEQ ID NO: 29 (HB22-33 Vκ sequence).

### Claim 35 (depends on 1)

The method of claim 1 wherein said antibody comprises VH and Vκ sequences selected from the group consisting of amino acids 1 to 97 of SEQ ID NO: 11 (HB22-7 VH sequence) and the amino acid sequence of SEQ ID NO: 23 (HB22-7 Vκ sequence); amino acids 1 to 100 of SEQ ID NO: 15 (HB22-23 VH sequence) and the amino acid sequence of SEQ ID NO: 27 (HB22-23 Vκ sequence); and amino acids 1 to 98 of SEQ ID NO: 17 (HB22-33 VH sequence) and the amino acid sequence of SEQ ID NO: 29 (HB22-33 Vκ sequence).

### Claim 36 (depends on 35)

The method of claim 35 wherein said antibody is chimeric.

### Claim 37 (depends on 35)

The method of claim 35 wherein said antibody is humanized.

### Claim 38 (depends on 35)

The method of claim 35 wherein said antibody is human.
